💥 Gate Square Event: #Post0GWinUSDT# 💥
Post original content on Gate Square related to 0G or the ongoing campaigns (Earn, CandyDrop, or Contract Trading Competition) for a chance to share 200 USDT rewards!
📅 Event Period: Sept 25, 2025, 18:00 – Oct 2, 2025, 16:00 UTC
📌 Related Campaigns:
Earn: Enjoy stable earnings
👉 https://www.gate.com/announcements/article/47290
CandyDrop: Claim 0G rewards
👉 https://www.gate.com/announcements/article/47286
Contract Trading Competition: Trade to win prizes
👉 https://www.gate.com/announcements/article/47221
📌 How to Participate:
1️⃣ Post original cont
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.